WHY IT'S IMPORTANT. Cycle Pharma's $8 per share proposal is an 80% premium to Vanda's last closing price, valuing the company at $488 million. The potential offer follows a 4.5% fall in Vanda's ...

Vanda acquired rights to U.S. and Canadian rights to PONVORY ® from Actelion Pharmaceuticals Ltd., a Johnson& Johnson Company. PONVORY ® is approved by the U.S. Food and Drug Administration and ...

In all, I maintain my buy recommendation on Vanda Pharmaceuticals with the 4.8/5 stars rating On a two years horizon, I expect the $50.24 price target to be reached.

Vanda Pharmaceuticals was incorporated in 2003 and is headquartered in Washington D.C. The company acquired a license to develop and commercialize Hetlioz in February 2004 from Bristol-Myers ...

HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months. Get the ...

Cycle Pharmaceuticals reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals for an all-cash consideration of $8.00 per Vanda share. Cycle said it is ...

Vanda Pharmaceuticals has seen an increase in net product sales this year — in a landscape the Covid-19 pandemic has generally challenged and after a rocky period for the D.C. biotech.

Vanda Pharmaceuticals Inc. VNDA shares are trading lower after Future Pak withdrew its proposal to purchase the company. “Consistent with the position indicated in its June 13, 2024 letter to ...

HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price ...

What happened Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) fell more than 19% today after the company announced it was pursuing legal action.